Aelix Therapeutics, a spin-off of HIVACAT and CataloniaBio & HealthTech member, has published positive results of the HIV therapeutic vaccine in Phase I/IIa clinical trial. The virus remained under control for 6 months without treatment in 40% of those vaccinated. Yesterday, the scientific team explained the results at the Conference on Retroviruses and Opportunistic Infections 2021, one of the most important international congresses on AIDS.
The AELIX-002 study is a randomised, double-blind, placebo-controlled study to assess the vaccine's safety, tolerability, immunogenicity and antiviral effect. It took place at a single centre in the Germans Trias i Pujol University Hospital, with 45 HIV-positive patients.
“This supports our vision to position the HTI vaccine as the backbone of future AIDS cure strategies in combination with other agents," explained José Luis Cabero, Aelix CEO. Aelix will open a financial round that will allow it to evaluate vaccine combinations with other agents in clinical trials with more participants.
Aelix was founded in 2015 by Jordi Naval, current Biocat CEO, Bonaventura Clotetand Christian Brander. One of the main investors is Ysios Capital.
Photo: José Luis Cabero and Christian Brander, CEO and Scientific Director of Aelix, respectively.
Comments